Literature DB >> 3020129

Syngeneic monoclonal internal image anti-idiotopes as prophylactic vaccines.

G N Gaulton, A H Sharpe, D W Chang, B N Fields, M I Greene.   

Abstract

A syngeneic monoclonal anti-idiotope that behaves as an internal image of the mammalian reovirus type 3 cellular attachment protein (viral hemagglutinin) was used in the syngeneic host for the induction of a prophylactic anti-viral antibody response. These studies were performed without the aid of co-stimulation by viral antigens. The high stringency of this system enables us to define the maximum constraints on the use of anti-idiotopes as anti-viral vaccines. We have used the murine BALB/c monoclonal IgM anti-idiotope 87.92.6 to study the idiotope and antigen specificity, kinetics, dose dependence, adjuvant, carrier, and valency requirements of anti-idiotope-induced anti-viral antibody responses. These studies show that the production of high titer neutralizing antibody requires a lengthy (60 day) immunization protocol, which includes the use of adjuvant and multivalent anti-idiotope, and is dependent on anti-idiotope concentrations of greater than 50 micrograms. When administered in this manner anti-idiotope can stimulate serotype-specific antibody responses across species barriers at levels comparable with those obtained after inoculation with virus. The practical efficacy of these reagents and procedures is documented by the ability of maternal immunization with anti-idiotope to confer complete protection in neonates from a potentially lethal reovirus type 3 viral infection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3020129

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Induction of a neutralizing immune response to human respiratory syncytial virus with anti-idiotypic antibodies.

Authors:  C Palomo; J P Albar; B García-Barreno; J A Melero
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

2.  Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic/antireceptor antibody: modeling of their three-dimensional structures.

Authors:  W V Williams; H R Guy; D H Rubin; F Robey; J N Myers; T Kieber-Emmons; D B Weiner; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

Review 3.  Idiotypic vaccines and infectious diseases.

Authors:  J R Hiernaux
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

4.  Development and characterization of an anti-idiotype antibody to the capsular polysaccharide of Neisseria meningitidis serogroup C.

Authors:  M A Westerink; A A Campagnari; M A Wirth; M A Apicella
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

Review 5.  Anti-idiotypic antibodies as vaccines against carbohydrate antigens.

Authors:  M A Westerink; M A Apicella
Journal:  Springer Semin Immunopathol       Date:  1993

6.  Protective anti-reovirus monoclonal antibodies and their effects on viral pathogenesis.

Authors:  K L Tyler; M A Mann; B N Fields; H W Virgin
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

7.  A protective monoclonal anti-idiotypic vaccine to lethal Semliki Forest virus infection in BALB/c mice.

Authors:  T A Oosterlaken; M Harmsen; S S Jhagjhoor-Singh; G L Ekstijn; C A Kraaijeveld; H Snippe
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

8.  Anti-idiotype vaccines for immunity to bacterial polysaccharides: induction of functional antibodies to polysaccharide antigens of Pseudomonas aeruginosa.

Authors:  J R Schreiber
Journal:  Springer Semin Immunopathol       Date:  1993

9.  Monoclonal anti-idiotypes induce neutralizing antibodies to enterovirus 70 conformational epitopes.

Authors:  J A Wiley; J Hamel; B R Brodeur
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

10.  Role of immune cells in protection against and control of reovirus infection in neonatal mice.

Authors:  H W Virgin; K L Tyler
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.